Home The Word Brain | My Amedeo FAQ Privacy About | ||||||||||
The 20K Word Road to Mandarin Proficiency By B. S. Kamps et al. |
Prostate Cancer |
Free Subscription
3 Anticancer Res |
Retrieve available abstracts of this week’s articles:
HTML format |
Single Articles |
AMEDEO Prostate Cancer is free of charge.
Biparametric MRI for Local Staging of Prostate Cancer: Current Status and Future
Applications.
Anticancer Res. 2024;44:463-470.
PubMed
Abstract available
Effectiveness of Magnetic Resonance Imaging/Ultrasound-guided Target Biopsy in
Detecting Clinically Significant Prostate Cancer.
Anticancer Res. 2024;44:679-686.
PubMed
Abstract available
Copy Number Gain in Androgen Receptors Predicts the Poor Prognosis in Japanese
Castration-resistant Prostate Cancer.
Anticancer Res. 2024;44:639-647.
PubMed
Abstract available
Evaluation of the tolerability and safety of [(225)Ac]Ac-PSMA-I&T in patients
with metastatic prostate cancer: a phase I dose escalation study.
BMC Cancer. 2024;24:146.
PubMed
Abstract available
Outcomes of robot-assisted laparoscopic extended pelvic lymph node dissection for
prostate Cancer.
BMC Urol. 2024;24:24.
PubMed
Abstract available
Prediction of Gleason score in prostate cancer patients based on radiomic
features of transrectal ultrasound images.
Br J Radiol. 2024;97:415-421.
PubMed
Abstract available
Multimodal radiomics based on 18F-Prostate-specific membrane antigen-1007 PET/CT
and multiparametric MRI for prostate cancer extracapsular extension prediction.
Br J Radiol. 2024;97:408-414.
PubMed
Abstract available
Does hormone therapy impact cognition in patients with prostate cancer? A
systematic review and meta-analysis.
Cancer. 2024 Feb 2. doi: 10.1002/cncr.35210.
PubMed
Abstract available
The impact of genomic biomarkers on a clinical risk prediction model for
upgrading/upstaging among men with favorable-risk prostate cancer.
Cancer. 2024 Jan 27. doi: 10.1002/cncr.35215.
PubMed
Abstract available
Advances of radiolabeled GRPR ligands for PET/CT imaging of cancers.
Cancer Imaging. 2024;24:19.
PubMed
Abstract available
A phase 1 study of acapatamab, a half-life extended, PSMA-targeting bispecific
T-cell engager for metastatic castration-resistant prostate cancer.
Clin Cancer Res. 2024 Feb 1. doi: 10.1158/1078-0432.CCR-23-2978.
PubMed
Abstract available
ERBB3 overexpression is enriched in diverse patient populations with
castration-sensitive prostate cancer and is associated with a unique AR activity
signature.
Clin Cancer Res. 2024 Feb 2. doi: 10.1158/1078-0432.CCR-23-2161.
PubMed
Abstract available
Updates on Management of Biochemical Recurrent Prostate Cancer.
Curr Treat Options Oncol. 2024 Jan 3. doi: 10.1007/s11864-023-01164.
PubMed
Abstract available
Metastatic Hormone-Sensitive Prostate Cancer in the Era of Doublet and Triplet
Therapy.
Curr Treat Options Oncol. 2024 Jan 4. doi: 10.1007/s11864-023-01173.
PubMed
Abstract available
Hypofractionated versus conventional fractionation external beam radiotherapy in
intermediate and high risk localized prostate cancer.
Discov Oncol. 2024;15:27.
PubMed
Abstract available
Impact of Prostate-specific Membrane Antigen Positron Emission
Tomography/Computed Tomography on Prostate Cancer Salvage Radiotherapy
Management: Results from a Prospective Multicenter Randomized Phase 3 Trial
(PSMA-SRT NCT03582774).
Eur Urol. 2024 Jan 29:S0302-2838(24)00013-7. doi: 10.1016/j.eururo.2024.
PubMed
Abstract available
Amount of Gleason Pattern 3 Is Not Predictive of Risk in Grade Group 2-4 Prostate
Cancer.
Eur Urol. 2024 Jan 25:S0302-2838(24)00007-1. doi: 10.1016/j.eururo.2024.
PubMed
Abstract available
Editorial Comment to Histological parameters and stromal desmoplastic status
affecting accurate diagnosis of extraprostatic extension of prostate cancer using
multi-parametric magnetic resonance imaging.
Int J Urol. 2024 Jan 29. doi: 10.1111/iju.15406.
PubMed
Revisiting the impact of antibiotics on prostate cancer risk: Beyond the gut
microbiota.
Int J Urol. 2024 Jan 29. doi: 10.1111/iju.15401.
PubMed
Impact of Weight Management on Obesity-Driven Biomarkers of Prostate Cancer
Progression.
J Urol. 2024 Feb 1:101097JU0000000000003849. doi: 10.1097/JU.0000000000003849.
PubMed
Abstract available
Intraductal Prostate Cancer Affinity for Lymphatic-Predominant Metastases Through
(18)F-DCFPyL?Prostate-Specific Membrane Antigen?Positron Emission Tomography/CT
Scans in Pretreatment Prostate Cancer Patients.
J Urol. 2024 Feb 1:101097JU0000000000003850. doi: 10.1097/JU.0000000000003850.
PubMed
Abstract available
Mapping the prostate cell family tree.
Nat Rev Cancer. 2024;24:96.
PubMed
The yin and yang of chromosomal instability in prostate cancer.
Nat Rev Urol. 2024 Feb 2. doi: 10.1038/s41585-023-00845.
PubMed
Abstract available
The complex interplay of modifiable risk factors affecting prostate cancer
disparities in African American men.
Nat Rev Urol. 2024 Feb 2. doi: 10.1038/s41585-023-00849.
PubMed
Abstract available
Thank you for your interest in scientific medicine.